Background: According to its new conceptualization, Alzheimer's disease (AD) has preclinical and symptomatic phases, and biomarker abnormality justifies the diagnosis of the disease. Methods: The conceptual validity of AD is assessed on the basis of the disease definitions of T. Szasz, R.E. Kendell and J.G. Scadding, C. Boorse, K.W.M. Fulford and J.C. Wakefield, as well as of the DSM-5 classification system. Results: The new AD conceptualization could fit the Szaszian disease definition, provided that AD biomarkers reflected the pathological hallmarks of a singular disease, but it seems that they do not. Moreover, preclinical AD does not yield a biological disadvantage, being a central criterion for justifying the presence of a disease according to the disease definition of Scadding and Kendell. In addition, it remains unclear whether abnormality of biomarkers in elderly people embodies a statistical deviation from normal ageing and a pathological characteristic. Furthermore, not all stages of AD are related to experiences of failure of intentional doing, which is the criterion of the disease definition of Fulford, whilst the Wakefieldian harmful dysfunction and the DSM-5 mental disorder criteria are fulfilled only in the symptomatic phases of the disease course. Discussion: Our analytical endeavours unveiled weak sides and the fuzzy boundaries of the new conceptualization of AD. Future refinements of the criteria should address them so that the validity of the AD concept is increased.

Keywords:
Alzheimer’s disease, New conceptualization, Disease
1.
George DR, Whitehouse PJ, Ballenger J: The evolving classification of dementia: placing the DSM-V in a meaningful historical and cultural context and pondering the future of ‘Alzheimer's'. Cult Med Psychiatry 2011;35:417-435.
2.
Perneczky R, Alexopoulos P, Kurz A: Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends Mol Med 2014;20:8-15.
3.
Minati L, Edginton T, Bruzzone MG, Giaccone G: Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 2009;24:95-121.
4.
Fang FC, Casadevall A: Reductionistic and holistic science. Infect Immun 2011;79:1401-1404.
5.
McKhann GM: Changing concepts of Alzheimer disease. JAMA 2011;305:2458-2459.
6.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, et al: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-629.
7.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
8.
Perneczky R, Pohl C, Sorg C, Hartmann J, Komossa K, Alexopoulos P, Wagenpfeil S, Kurz A: Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age Ageing 2006;35:240-245.
9.
Perneczky R, Pohl C, Sorg C, Hartmann J, Tosic N, Grimmer T, Heitele S, Kurz A: Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. Int J Geriatr Psychiatry 2006;21:158-162.
10.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
11.
Whitehouse PJ, George DR, D'Alton S: Describing the dying days of ‘Alzheimer's disease'. J Alzheimers Dis 2011;24:11-13.
12.
Mattsson N, Blennow K, Zetterberg H: Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 2010;48:603-607.
13.
Whitehouse PJ: The end of Alzheimer's disease - from biochemical pharmacology to ecopsychosociology: a personal perspective. Biochem Pharmacol 2014;88:677-681.
14.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, et al: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-333.
15.
Beach TG, Monsell SE, Phillips LE, Kukull W: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers 2005-2010. J Neuropathol Exp Neurol 2012;71:266-273.
16.
Khachaturian ZS: Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:253-256.
17.
George DR, Qualls SH, Camp CJ, Whitehouse PJ: Renovating Alzheimer's: ‘constructive' reflections on the new clinical and research diagnostic guidelines. Gerontologist 2013;53:378-387.
18.
Szasz TS: The myth of mental health. Am Psychol 1960;15:113-118.
19.
Bracken P, Thomas P: From Szasz to Foucault: on the role of critical psychiatry. Philos Psychiatry Psychol 2010;17:219-228.
20.
Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, et al: A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 2014;515:274-278.
21.
Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, et al: Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012;71:362-381.
22.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E: Alzheimer's disease. Lancet 2011;377:1019-1031.
23.
Skillback T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, et al: Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain 2015;138:2716-2731.
24.
Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, Honigschnabl S, Reiner-Concin A, Heinzl H, Jungwirth S, et al: Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013;126:365-384.
25.
Alexopoulos P, Roesler J, Thierjung N, Werle L, Buck D, Yakushev I, Gleixner L, Kagerbauer S, Ortner M, Grimmer T, et al: Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2015, Epub ahead of print.
26.
Kendell RE: The concept of disease and its implications for psychiatry. Br J Psychiatry 1975;127:305-315.
27.
Scadding JG: Diagnosis: the clinician and the computer. Lancet 1967;ii:877-882.
28.
Scadding JG: Health and disease: what can medicine do for philosophy? J Med Ethics 1988;14:118-124.
29.
Jack CR Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, et al: Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 2014;13:997-1005.
30.
Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF: Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154:642-648.
31.
Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Ostbye T, Rockwood K, Hogan DB: A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344:1111-1116.
32.
Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B: Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999;52:737-743.
33.
Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST: Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol 2005;62:779-784.
34.
Wu CY, Chou YC, Huang N, Chou YJ, Hu HY, Li CP: Cognitive impairment assessed at annual geriatric health examinations predicts mortality among the elderly. Prev Med 2014;67:28-34.
35.
Santabarbara J, Lopez-Anton R, Marcos G, De-la-Camara C, Lobo E, Saz P, Gracia-Garcia P, Ventura T, Campayo A, Rodriguez-Manas L, et al: Degree of cognitive impairment and mortality: a 17-year follow-up in a community study. Epidemiol Psychiatr Sci 2015, Epub ahead of print.
36.
Sachs GA, Carter R, Holtz LR, Smith F, Stump TE, Tu W, Callahan CM: Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med 2011;155:300-308.
37.
Balasubramanian AB, Kawas CH, Peltz CB, Brookmeyer R, Corrada MM: Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia. Neurology 2012;79:915-921.
38.
Boorse C: On the distinction between disease and illness. Philos Publ Affairs 1975;5:49-68.
39.
Wakefield JC: The biostatistical theory versus the harmful dysfunction analysis. 1. Is part-dysfunction a sufficient condition for medical disorder? J Med Philos 2014;39:648-682.
40.
Knochel C, Oertel-Knochel V, Bittner R, Stablein M, Heselhaus V, Prvulovic D, Fusser F, Karakaya T, Pantel J, Maurer K, Linden DE: Consolidation time affects performance and neural activity during visual working memory. Psychiatry Res 2015;231:33-41.
41.
Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, Johnson KA: Functional alterations in memory networks in early Alzheimer's disease. Neuromol Med 2010;12:27-43.
42.
Fulford KW: ‘What is (mental) disease?' An open letter to Christopher Boorse. J Med Ethics 2001;27:80-85.
43.
Wakefield JC: The concept of mental disorder. On the boundary between biological facts and social values. Am Psychol 1992;47:373-388.
44.
Brulde B: Wakefield's hybrid account of mental disorder. World Psychiatry 2007;6:163-164.
45.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 5. Washington, American Psychiatric Association, 2013.
46.
Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, Fratiglioni L, Hooshmand B, Khachaturian AS, Schneider LS, et al: Advances in the prevention of Alzheimer's disease and dementia. J Intern Med 2014;275:229-250.
47.
Whitehouse PJ, George DR: Uncertain progress on the fuzzy boundaries of Alzheimer's disease: reading between the guidelines. J Alzheimers Dis 2011;26:1-5.
48.
Sperling R, Mormino E, Johnson K: The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 2014;84:608-622.
49.
Yiannopoulou KG, Papageorgiou SG: Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 2013;6:19-33.
50.
Whitehouse P: The challenges of cognitive aging: integrating approaches from science to intergenerational relationships. J Alzheimers Dis 2013;36:225-232.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.